We trace the move from silver bullets to synergy, showing why Alzheimer’s demands combination therapy that hits amyloid, tau, inflammation, and metabolism while pairing drugs with precise lifestyle changes. We explain how adaptive trials, repurposed medicines, and prevention strategies could push past today’s 30 percent ceiling.• scale of aging demographics and the rising Alzheimer’s burden• limits of symptom drugs and why plaque clearance alone falls short• the 30 percent benefit of antibodies and the remaining gap• rationale for combination therapy across multiple pathways• GLP‑1 agonists, metformin, and drug repurposing logic• senolytics and anti‑tau plus anti‑amyloid combinations• adaptive trial designs integrating background antibody use• funding challenges for off‑patent drugs and AI data needs• pivot toward multimodal care and prevention strategiesThis podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

Ver todos los episodios